Share on StockTwits

Galectin Therapeutics (NASDAQ:GALT) CEO Peter G. Traber acquired 1,000 shares of the stock on the open market in a transaction dated Wednesday, August 13th. The stock was purchased at an average cost of $4.42 per share, for a total transaction of $4,420.00. Following the acquisition, the chief executive officer now directly owns 97,333 shares in the company, valued at approximately $430,212. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Galectin Therapeutics (NASDAQ:GALT) traded up 5.71% during mid-day trading on Thursday, hitting $4.63. 602,317 shares of the company’s stock traded hands. Galectin Therapeutics has a one year low of $4.28 and a one year high of $19.11. The stock has a 50-day moving average of $10.7 and a 200-day moving average of $12.87. The company’s market cap is $102.1 million.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, analysts predict that Galectin Therapeutics will post $-0.93 earnings per share for the current fiscal year.

GALT has been the subject of a number of recent research reports. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.

Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.

Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.